News

Pfizer Inc. and International Business Machines Corporation (IBM) announced a collaborative research project to advance the development of remote medical monitoring solutions that aim to transform how clinicians deliver care to people with Parkinson’s disease. The first-of-its-kind experimental approach employed by Pfizer and IBM will harness a…

Italy-based biopharma Newron Pharmaceuticals S.p.A. and its partner, international pharmaceutical company Zambon S.p.A., both dedicated to finding treatments for diseases of the central nervous system (CNS), recently announced their acknowledgement and support of World Parkinson’s Disease Awareness Day, which was on April 11. Additionally, both companies emphasized their commitment to…

Neurologists reported that drugs commonly prescribed for Parkinson’s disease are associated in some people with impulse control disorders such as pathological gambling and binge eating. The article, “Treatment of impulse control disorders in Parkinson’s disease: Practical considerations and future directions,” was published in the journal Expert Review of…

The Colorado Neurological Institute (CNI), a research discovery nonprofit that focuses on neurological care, will host its inaugural Spotlight on Hope gala at 6 p.m. April 15 at the Ritz-Carlton in Denver. The presenting sponsor is Radiology Imaging Associates, a leader in diagnostic imaging and interventional radiology. The Spotlight on Hope…

The Journal of Parkinson’s Disease (JPD) is working to promote Parkinson’s research by helping its researchers find new sources of financial support — through a free service, the Parkinson’s Disease Funding Analyzer (PDFA), now available on its website and containing in-depth data on 114 funding sources in 40 countries. “This is a unique and remarkable tool…

ACADIA Pharmaceuticals accounced that the FDA Psychopharmacologic Drugs Advisory Committee voted that the benefits of Nuplazid (pimavanserin) for the treatment of Parkinson’s disease-related psychosis outweighed the risks of the drug. Nuplazid is a selective serotonin inverse agonist and, if approved, will establish a new and distinctly different pharmacological approach…

Stem cell therapy, which many people living with Parkinson’s disease have long pinned hope on as a potential treatment or even a cure, is finally advancing to clinical trial stage. The recent announcement of a Phase 1/2a clinical trial involving transplantation of stem cells into the first human subjects is…

Living Cell Technologies announced that it has received approval from the Auckland Hospital Research Review Committee to begin a Phase 2b clinical trial evaluating its lead product, NTCELL, as a potential treatment for Parkinson’s disease. Patient recruitment for the trial is now underway, the company said in a press release. NTCELL is an…

The free Hope Flies Health Series Webinar: Research Connecting Parkinson’s Disease and Mitochondrial Disease is scheduled for 1 p.m. Eastern Standard Time on Wednesday, April 6. The event is hosted by the Foundation for Mitochondrial Medicine (FMM) and partners Michael J. Fox Foundation (MJFF), Wilkins Parkinson’s Foundation and…

mPower, a Parkinson’s disease (PD) iPhone app developed by Sage Bionetworks and a team of neurologists at the University of Rochester Medical Center (URMC), marked the first year of its release by being highlighted in Apple Inc.’s “Loop You In” special product launch event on March 21, 2016.